News

Icon dampens its outlook despite a strong quarter

Icon came through with double-digit revenue growth in the first quarter, but currency fluctuations have the Irish CRO scaling back its expectations for the full year.

INC swings to profit and dials up its revenue expectations

CRO INC Research boosted its sales by 14.5% in the first quarter, returning to profitability as it blueprints a big year.

BioClinica recruits a new eClinical president amid rapid expansion

BioClinica has poached an Oracle exec to lead its banner eClinical division, part of its long-term expansion efforts.

WuXi deepens its genomic ties with latest partnership

Months removed from buying its way into the world of Big Data genomics, Chinese CRO WuXi PharmaTech has partnered up with DNAnexus to take its technology to the cloud.

India's Biocon eyes an IPO for its in-house CRO

Indian biotech giant Biocon is planning to take Syngene, its in-house CRO, public in an IPO on the local exchange.

Sartorius snags U.K. CRO BioOutsource with an eye on biosimilars

Biopharma production specialist Sartorius Stedim Biotech has acquired BioOutsource, a U.K. CRO focused on the growing demand for knockoffs of top-selling biologics.

PPD reaches into China with a new central lab

PPD has opened a new central lab facility in Shanghai, expanding its testing services into China as it stretches out around the globe.

Catalent wraps up a $52M manufacturing expansion

Catalent doubled its capacity at a Kentucky manufacturing facility, wrapping up a $52 million project with plans to add about 140 new workers.

Quintiles deepens its Latin American ties with Argentine partnership

Quintiles is further entrenching itself in Latin America, striking a deep-rooted alliance with a research site in Buenos Aires to widen its global network of trusted partners.

Recipharm bets on a U.S. biotech with an R&D joint venture

Swedish contract drug developer Recipharm has signed a deal with Virginia's Synthonics, investing in the biotech and lending its expertise in the development of new compounds.

Two ophthalmology CROs join forces for ocular R&D

Iris Pharma and Oculos Clinical Research, two CROs focused on the eye, have inked a strategic alliance to boost their profiles in the contracting world.

Aptuit pairs up with an Italian CRO for drug discovery

U.S. contractor Aptuit has signed a deal with Italy's Axxam to team up on early-stage R&D services, pooling their resources to better compete for projects.

Clinipace bags CRO Accovion in its latest global buyout

Serial acquirer Clinipace has bought up European CRO Accovion, striking its 6th deal in as many years as it seeks to expand its global reach.

Protea buys CRO vivoPharm for preclinical expertise

West Virginia bioanalytics outfit Protea Biosciences has acquired preclinical researcher vivoPharm to expand in the world of early-stage oncology development.

WuXi gets a manufacturing subsidiary on the Chinese stock market

Chinese CRO WuXi PharmaTech has pushed one of its manufacturing subsidiaries onto the local stock market, selling off a stake as it focuses on its high-growth biologics business.

Parexel partners up for clinical trial education

CRO giant Parexel International has unveiled three new education programs in partnership with schools around the world, lending its expertise in hopes of training the next generation of clinical researchers.

Catalent reaches into Australia with latest buyout

Catalent is buying a drug packaging operation in Australia, extending its global reach with a focus on the Asia-Pacific region.

PPD sets off in Japan with SNBL joint venture

PPD and partner Shin Nippon Biomedical Laboratories have hit the ground running with their Japanese joint venture, closing a deal that will see them join forces in the country's growing market for clinical trials.

AMRI shutters another plant with an eye on its bottom line

Contract drug developer AMRI is closing down a U.K. manufacturing operation as part of its across-the-board change in strategy, an effort to get back to growth after a rough string of quarters.

Piramal sells its CRO division to India's Indoco

Indian conglomerate Piramal has sold off its CRO business to Indoco Remedies, getting rid of a business "not considered strategic in nature," according to the company.